var data={"title":"Atropine and pralidoxime: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Atropine and pralidoxime: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/262716?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=atropine-and-pralidoxime-drug-information\" class=\"drug drug_general\">see &quot;Atropine and pralidoxime: Drug information&quot;</a> and <a href=\"topic.htm?path=atropine-and-pralidoxime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Atropine and pralidoxime: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801638\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">FDA Extends DuoDote Expiration Dates - Update</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is alerting health care providers that additional lots of Meridian Medical Technologies&rsquo; DuoDote autoinjectors can be used beyond the manufacturer's labeled expiration date. The FDA is not requiring or recommending that the identified lots be relabeled with the new use date.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">This updates the FDA's March 2015 alert. More information can be found at: <a target=\"_blank\" href=\"http://www.fda.gov/drugs/drugsafety/ucm376367.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=SHauxSdf9qNc6lLK16E8INPcg8wCB/kOstw2QyQh7uwyO/YBJKFbxu30FZMnVSBkHXldO3N/LQMWpftPSZeqXxchtFxAS8t21dsaq9VGKcY0QNuH5Dn+sHPN6PZ7cKKw&amp;TOPIC_ID=116889\" target=\"_blank\">http://www.fda.gov/drugs/drugsafety/ucm376367.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302652\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ATNAA;</li>\n      <li>Duodote</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28119937\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticholinergic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28119940\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=atropine-and-pralidoxime-drug-information\" class=\"drug drug_general\">see &quot;Atropine and pralidoxime: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Organophosphate insecticide or nerve agent poisoning:</b> <b>Note:</b> If exposure is known or suspected, antidotal therapy should be given immediately as soon as symptoms appear (critical to administer immediately in case of soman exposure since its adverse effects develop within minutes). Only health care providers who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication should administer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents weighing &gt;41 kg: DuoDote (atropine 2.1 mg/pralidoxime 600 mg per autoinjector):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild symptoms (&ge;2 mild symptoms): IM: 1 injection (wait 10 to 15 minutes for effect); if after 10 to 15 minutes no severe symptoms emerge, no further injections are indicated; if any severe symptoms emerge at any point following initial injection, repeat dose by giving 2 additional injections in rapid succession. Transport to medical care facility.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe symptoms (&ge;1 severe symptom): IM: 3 injections in rapid succession. Transport to medical care facility.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum cumulative dose: 3 injections unless medical care support (eg, hospital, respiratory support) is available</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Symptoms of organophosphate insecticide or nerve agent poisoning, as provided by manufacturer in the DuoDote product labeling to guide therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild symptoms: Airway secretions increased, blurred vision, bradycardia, breathing difficulties, chest tightness, drooling, miosis, nausea, vomiting, runny nose, salivation, stomach cramps (acute onset), tachycardia, teary eyes, tremors/muscular twitching, wheezing/coughing</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe symptoms: Breathing difficulties (severe), confused/strange behavior, convulsions, copious secretions from lung or airway, involuntary urination/defecation, muscular twitching/generalized weakness (severe), unconsciousness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Organophosphate insecticide or nerve agent poisoning:</b> IM: <b>Note:</b> If exposure is suspected, antidotal therapy should be given immediately as soon as symptoms appear (critical to administer immediately in case of soman exposure). Definitive medical care should be sought after any injection given. One injection only may be given as self-aid. If repeat injections needed, administration must be done by another trained individual. Emergency medical personnel who have self-administered a dose must determine capacity to continue to provide care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ATNAA:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild symptoms (some or all mild symptoms): Self-Aid or Buddy-Aid: 1 injection (wait 10 to 15 minutes for effect); if the patient is able to ambulate, and knows who and where they are, then no further injections are needed. If symptoms still present: Buddy-Aid: May repeat 1 to 2 more injections</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe symptoms (if most or all): Buddy-Aid: If no self-aid given, 3 injections in rapid succession; if 1 self-aid injection given, 2 injections in rapid succession</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum cumulative dose: 3 injections</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Symptoms of organophosphate insecticide or nerve agent poisoning, as provided by the manufacturer in the ATNAA product labeling to guide therapy: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild symptoms: Breathing difficulties, chest tightness, coughing, difficulty in seeing, drooling, headache, localized sweating and muscular twitching, miosis, nausea (with or without vomiting), runny nose, stomach cramps, tachycardia (followed by bradycardia), wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe symptoms: Bradycardia, confused/strange behavior, convulsions, increased wheezing and breathing difficulties, involuntary urination/defecation, miosis (severe), muscular twitching/generalized weakness (severe), red/teary eyes, respiratory failure, unconsciousness, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>DuoDote:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild symptoms (&ge;2 mild symptoms): 1 injection (wait 10 to 15 minutes for effect); if after 10 to 15 minutes no severe symptoms emerge, no further injections are indicated; if any severe symptoms emerge at any point following the initial injection, repeat dose by giving 2 additional injections in rapid succession. Transport to medical care facility.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe symptoms (&ge;1 severe symptom): 3 injections in rapid succession. Transport to medical care facility.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum cumulative dose: 3 injections unless medical care support (eg, hospital, respiratory support) is available</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Symptoms of organophosphate insecticide or nerve agent poisoning, as provided by manufacturer in the DuoDote product labeling to guide therapy: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild symptoms: Airway secretions increased, blurred vision, bradycardia, breathing difficulties, chest tightness, drooling miosis, nausea, vomiting, runny nose, salivation, stomach cramps (acute onset), tachycardia, teary eyes, tremors/muscular twitching, wheezing/coughing</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe symptoms: Breathing difficulties (severe), confused/strange behavior, convulsions, copious secretions from lung or airway, involuntary urination/defecation, muscular twitching/generalized weakness (severe)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> Use caution in renal impairment; pralidoxime is renally eliminated; patients with severe renal impairment may require less frequent dosing following the initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment: </b>There are no specific dosage adjustments provided in manufacturer's labeling; patients with severe hepatic impairment may require less frequent dosing following the initial dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302689\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ATNAA, Duodote: Atropine 2.1 mg/0.7 mL and pralidoxime chloride 600 mg/2 mL [contains benzyl alcohol; prefilled autoinjector]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302654\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217266\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATNAA (<b>A</b>ntidote <b>T</b>reatment-<b>N</b>erve <b>A</b>gent <b>A</b>uto-Injector) is only available for use by US Armed Forces military personnel. Information on distribution is available at Defense Services Supply Center-Philadelphia at 215-737-2341.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duodote is only available for use by trained emergency medical services personnel to treat civilians. Distribution is limited to directly from manufacturer (Meridian Medical Technologies, Inc) to emergency medical service organizations or their suppliers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28119941\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DuoDote: Administer IM into the mid-lateral thigh. Hold the device firmly at the center with the green tip (needle end) pointing down; remove the gray safety release with the other hand; do not touch the green tip at any time. The device is now ready for administration into the mid-lateral thigh; removal of clothing is not necessary, but pockets should be empty. If patient does not have a lot of fat at the injection site, bunch up thigh tissue for a thicker injection area. Firmly push the green tip against the mid-lateral thigh. Hold firmly in place until auto-injector triggers and continue to hold for 10 seconds after the device has triggered. The needle does not retract; after administration, the needle should be visible; if the needle is not visible, repeat the above steps. After use, bend the needle against a hard surface to avoid accidental injury.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATNAA: Administer IM in the lateral thigh muscle or buttocks. The first dose may be self-administered; subsequent doses must be administered by a buddy. Remove the gray safety cap from the back end; place the front end on the outer thigh or buttocks and push hard to activate the injector. Hold firmly in place for 10 seconds. After use, bend the needle into a hook shape against a hard surface.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302674\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); avoid freezing. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> As of May 2014, for certain lots of DuoDote, the US Food and Drug Administration (FDA) has granted extended expiration dating for up to 3 years beyond the manufacturer's labeled expiration dating. Further information may be found at <a target=\"_blank\" href=\"http://www.fda.gov/drugs/drugsafety/ucm376367.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=SHauxSdf9qNc6lLK16E8INPcg8wCB/kOstw2QyQh7uwyO/YBJKFbxu30FZMnVSBkHXldO3N/LQMWpftPSZeqXxchtFxAS8t21dsaq9VGKcY0QNuH5Dn+sHPN6PZ7cKKw&amp;TOPIC_ID=116889\" target=\"_blank\">http://www.fda.gov/drugs/drugsafety/ucm376367.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28119938\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DuoDote: Treatment of poisoning by organophosphate nerve agents (eg, tabun, sarin, soman) or organophosphate insecticides for use by trained emergency medical services personnel (FDA approved in pediatric patients weighing &gt;41 kg and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATNAA: Treatment of poisoning in patients who have been exposed to organophosphate nerve agents (eg, tabun, sarin, soman) that have acetylcholinesterase-inhibiting activity for self- or buddy-administration by military personnel (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302669\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reactions reported with Duodote. Also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Transient increase of blood pressure (usually occurring 15 minutes after administration and returning to baseline 4 hours post-dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Hypertonia (at injection site; mild-to-moderate)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site (mild-to-moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302663\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">No contraindications exist in the treatment of life-threatening organophosphate insecticide or nerve agent poisoning</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302664\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atropinization: Signs of atropinization (eg, flushing, mydriasis, tachycardia, dryness of mouth or nose) may occur earlier than expected with the use of a combination product as compared to atropine alone. Monitor effects closely when administering subsequent injections as necessary. The presence of these effects is not indicative of the success of therapy. Reversal of bronchial secretions is the preferred indicator of success.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthermia: Atropine may inhibit sweating and possibly lead to heat-related injury or hyperthermia in patients exposed to warm environments or exercise.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b> The following diseases are relative precautions only when symptoms of poisoning are <b>not</b> severe:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart disease, arrhythmias (eg, atrial flutter), severe CAD, or history of recent MI; treatment-related blood pressure increases and tachycardia may lead to ischemia, precipitate an MI, or increase arrhythmogenic potential.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic lung disease: Use with caution in patients with chronic lung disease; may cause inspiration of bronchial secretions and formation of dangerous viscid plugs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; effects of atropine may be prolonged in severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may precipitate myasthenic crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Narrow-angle glaucoma: Use with caution in patients with severe narrow-angle glaucoma; may precipitate acute glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia: Use with caution in patients with prostatic hyperplasia; may cause urinary retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pyloric stenosis: Use with caution in patients with pyloric stenosis; may cause complete pyloric obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in renal impairment; pralidoxime is excreted renally and the effects of atropine may be prolonged in severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: May be more sensitive to the anticholinergic effects of atropine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May be more sensitive to the anticholinergic effects of atropine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Clinical symptoms consistent with highly-suspected organophosphate insecticide or nerve agent poisoning should be treated with antidote immediately; administration should not be delayed for confirmatory laboratory tests. Treatment should always include proper evacuation and decontamination procedures; medical personnel should protect themselves from inadvertent contamination. Antidotal administration is intended only for initial management; definitive and more extensive medical care is required following administration. Individuals should not rely solely on antidote for treatment, as other supportive measures (eg, artificial respiration) may still be required. Continued administration of additional doses in asymptomatic patients may result in atropine toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51113947\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">CNS effects (eg, restlessness, tremor, fatigue, locomotor difficulties, delirium, hallucinations) are often seen earlier and at lower doses in pediatric patients compared to adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298795\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302671\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=116889&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Atropine (Systemic) may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): Atropine (Systemic) may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Atropine (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Atropine (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302658\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302659\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Reproduction studies have not been conducted with this combination. Also refer to individual agents. The risk:benefit ratio must be considered in pregnant patients who have been exposed to a nerve agent such as sarin. While adequate studies have not been conducted, survival of the mother may be dependent upon administering atropine and pralidoxime.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28119942\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory status, ABGs, pulse oximeter; body temperature (especially in warm climates); blood pressure (peak effect occurs ~15 minutes after administration); symptoms of poisoning</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28119943\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Direct measurement of RBC acetylcholinesterase activity provides a measure of degree of toxicity, although symptoms may not correlate with degree of inactivation unless activity reduced to &lt;50%. Sequential measurement (if rapidly available) may help to determine the effectiveness of oxime therapy. Plasma (or pseudo) cholinesterase activity is more easily performed, but does not correlate well with the severity and should not be used to guide therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302675\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;\">Atropine: Functions as a competitive antagonist of acetylcholine at muscarinic receptors in the peripheral and central nervous system, thus reducing the symptoms of parasympathetic overstimulation resulting from excess acetylcholine caused by organophosphate insecticide or nerve agent poisoning. The parasympatholytic action of atropine decreases oral and respiratory secretions, relieves airway constriction, and attenuates the bradycardia induced by organophosphate insecticides and nerve agents. Antagonizes acetylcholine accumulation at respiratory center and may reduce centrally-mediated respiratory paralysis. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pralidoxime: An oxime which functions by way of nucleophilic attack on the ester site of the acetylcholinesterase enzyme which has been deactivated by phosphorylation. Displacement of the phosphoryl group allows reactivation of acetylcholinesterase&rsquo;s hydrolytic activity, thus permitting renewed catalysis of accumulated acetylcholine. Destruction of accumulated acetylcholine allows for restoration of normal functioning at neuromuscular junctions and relief from respiratory muscle paralysis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4302678\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28119944\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Evacuation and decontamination procedures should be undertaken as soon as possible. Medical personnel need to protect themselves from accidental exposure. Primary prophylaxis against organophosphate  nerve agents should always consist of appropriate protective garments and masks. Organophosphate agents are well absorbed through skin, lungs, and GI tract. They are usually described as having a petroleum or garlic like odor. Once absorbed, organophosphate agents bind to acetylcholinesterase (also known as RBC acetylcholinesterases) and inactivate the enzyme. Acetylcholinesterases catalyze the hydrolysis of acetylcholine to choline and acetic acid; therefore, once inactivated excess acetylcholine accumulates.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Clinical symptoms of toxicity are associated with cholinergic excess and involve the autonomic nervous system, CNS, and neuromuscular junction. Clinical features of acute cholinergic toxicity include bradycardia, miosis, lacrimation, salivation, bronchorrhea, bronchospasm, emesis and diarrhea. At times, mydriasis and tachycardia may be observed. 100% oxygen and fluid resuscitation are important initial steps in management. Onset and duration of clinical features consistent with poisoning vary depending on agent and route of exposure; therefore, every effort should be made to identify poisoning agent. In addition, time interval to &ldquo;aging&rdquo; process (irreversible binding between organophosphates and acetylcholinesterase) vary depending on nerve agent. Once &ldquo;aging&rdquo; has occurred, oxime therapy (eg, pralidoxime) is ineffective, thus making timing of antidote administration critical, particularly in the case of soman exposure where &ldquo;aging&rdquo; process occurs within minutes of exposure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324114\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (DuoDote Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.1-600 mg (2.7 mL): $60.97</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ATNAA (atropine and pralidoxime) [prescribing information]. Columbia, MD: Meridian Medical Technologies Inc; April 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DuoDote (atropine and pralidoxime) [prescribing information]. Columbia, MD: Meridian Medical Technologies; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leikin JB, Thomas RG, Walter FG, et al, &ldquo;A Review of Nerve Agent Exposure for the Critical Care Physician,&rdquo; <i>Crit Care Med</i>, 2002, 30(10):2346-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-and-pralidoxime-pediatric-drug-information/abstract-text/12394966/pubmed\" target=\"_blank\" id=\"12394966\">12394966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rebmann T, Clements BW, Bailey JA, et al, &quot;Organophosphate Antidote Auto-Injectors vs Traditional Administration: A Time Motion Study,&quot; <i>J Emerg Med</i>, 2009, 37(2):139-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-and-pralidoxime-pediatric-drug-information/abstract-text/18514464/pubmed\" target=\"_blank\" id=\"18514464\">18514464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandilands EA, Good AM, and Bateman DN, &quot;The Use of Atropine in a Nerve Agent Response with Specific Reference to Children: Are Current Guidelines Too Cautious?&quot; <i>Emerg Med J</i>, 2009, 26(10):690-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-and-pralidoxime-pediatric-drug-information/abstract-text/19773481/pubmed\" target=\"_blank\" id=\"19773481\">19773481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinbroum AA, &ldquo;Pathophysiological and Clinical Aspects of Combat Anticholinesterase Poisoning,&rdquo; <i>Brit Med Bulletin</i>, 2005, 72:119-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-and-pralidoxime-pediatric-drug-information/abstract-text/15845747/pubmed\" target=\"_blank\" id=\"15845747\">15845747</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 116889 Version 4.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F22801638\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F4302652\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F28119937\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F28119940\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F4302689\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F4302654\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11217266\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28119941\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F4302674\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28119938\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4302669\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F4302663\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F4302664\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F51113947\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298795\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F4302671\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F4302658\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4302659\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28119942\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F28119943\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4302675\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F4302678\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F28119944\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324114\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/116889|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=atropine-and-pralidoxime-drug-information\" class=\"drug drug_general\">Atropine and pralidoxime: Drug information</a></li><li><a href=\"topic.htm?path=atropine-and-pralidoxime-patient-drug-information\" class=\"drug drug_patient\">Atropine and pralidoxime: Patient drug information</a></li></ul></div></div>","javascript":null}